Precigen’s (PGEN) Market Outperform Rating Reaffirmed at JMP Securities

Precigen (NASDAQ:PGEN)‘s stock had its “market outperform” rating reiterated by equities researchers at JMP Securities in a note issued to investors on Tuesday,Benzinga reports. They currently have a $5.00 target price on the biotechnology company’s stock. JMP Securities’ price objective points to a potential upside of 342.48% from the stock’s current price.

Separately, HC Wainwright reiterated a “buy” rating and set a $4.00 target price on shares of Precigen in a research report on Friday, November 15th. Two equities research analysts have rated the stock with a sell rating and four have issued a buy rating to the company. According to data from MarketBeat, Precigen presently has a consensus rating of “Hold” and an average price target of $6.33.

Precigen Stock Up 4.1 %

Shares of PGEN opened at $1.13 on Tuesday. Precigen has a 12 month low of $0.65 and a 12 month high of $1.93. The firm’s 50 day moving average is $0.90 and its 200-day moving average is $1.07.

Institutional Investors Weigh In On Precigen

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Traphagen Investment Advisors LLC acquired a new position in shares of Precigen during the 3rd quarter worth $29,000. Stifel Financial Corp raised its stake in Precigen by 94.9% during the third quarter. Stifel Financial Corp now owns 32,200 shares of the biotechnology company’s stock worth $30,000 after acquiring an additional 15,680 shares in the last quarter. SG Americas Securities LLC raised its stake in Precigen by 44.2% during the third quarter. SG Americas Securities LLC now owns 45,063 shares of the biotechnology company’s stock worth $43,000 after acquiring an additional 13,823 shares in the last quarter. AQR Capital Management LLC lifted its holdings in shares of Precigen by 56.7% in the second quarter. AQR Capital Management LLC now owns 50,002 shares of the biotechnology company’s stock worth $79,000 after acquiring an additional 18,097 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. boosted its stake in shares of Precigen by 86.6% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 55,337 shares of the biotechnology company’s stock valued at $52,000 after purchasing an additional 25,681 shares in the last quarter. 33.51% of the stock is currently owned by institutional investors.

About Precigen

Precigen, Inc operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar.